U.S. Food And Drug Administration (FDA)

Contraceptive knowledge gaps, Adolescent awareness of OTC contraception, DMPA and meningioma risk, Implicit bias in contraception counseling, PrEP & STI Risk

HPV self-collection, asynchronous telehealth abortion studies, young people and permanent contraception access, clinician confidence gaps in abortion navigation, shifting contraceptive preferences postpartum

What providers need to know when talking with patients about evidence-based recommendations for IUD and implant duration of use and effectiveness

Answers for pharmacists (and other providers) about the current status of mifepristone.

What providers need to know about the December 2022 updates to levonorgestrel emergency contraception (LNG-EC) labeling.

Continued support for misoprostol-only regimens for medication abortion and self-managed abortion between nine and 16 weeks gestation, the use of home pregnancy tests for follow-up care after a telehealth medication abortion, where adolescents and young adults go online to get abortion information, and disparities in recommended retesting for women with trichomonas vaginalis infections.

What providers need to know to answer patients' questions about OTC birth control pills.

Perceived pain and sedation dosing during abortion procedures by demographics, PAPP-A as a novel screening for gestational age before medication abortion, patient experiences with progestin-only pills and attitudes towards OTC access.